Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career Scientists
The Foundation for Angelman Syndrome Therapeutics (FAST) is proud to announce a new partnership with the American Society of Gene & Cell Therapy (ASGCT) to advance Angelman syndrome research by supporting early-career scientists focused on translational science, cell and gene targeted therapies, and neuroscience innovation.
Through ASGCT’s prestigious Career Development Awards, FAST will fund up to three additional $100,000 grants for projects focused on:
Neuron-targeted therapeutics for Angelman syndrome
High-risk, high-reward approaches to rare disease treatment
Translational science with the potential to move gene and cell therapies toward clinical application
This collaboration represents more than a funding opportunity; it is a shared commitment to the scientific rigor, innovation, and urgency required to make meaningful progress in rare neurological disease research.
"This is an opportunity to recruit additional scientific rigor into the Angelman syndrome research community by supporting early career researchers to advance cell and gene therapy for Angelman syndrome directly," said Dr. Allyson Berent, Chief Science Officer at FAST. "ASGCT is the leading world-renowned cell and gene therapy society that embodies the quality and rigor in research that FAST supports. Working with ASGCT to advance the next generation of incredible scientific discoveries, focused on Angelman syndrome, is a true honor."
By aligning with ASGCT—the global leader in cell and gene therapy—FAST is taking an intentional step to inspire innovation, attract top research talent, and ensure sustained momentum in Angelman syndrome therapeutics. These awards are designed to support the next generation of scientists working at the intersection of genetic medicine, neuroscience, and rare disease treatment. ASGCT has shown year after year that they are making genetic cures a reality.
The partnership builds on FAST’s broader mission: accelerating the path to effective Angelman syndrome treatments by supporting bold science and the people behind it. From discovery through development, FAST is committed to research that brings hope, options, and ultimately lifesaving therapies to families impacted by Angelman syndrome.
How to Apply
Researchers applying to ASGCT’s Career Development Awards who wish to be considered for FAST support must indicate “#FAST” in the subject line of their submission. The deadline to apply is August 1, 2025.
To learn more and apply, visit: ASGCT Career Development Awards Page